Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patients by M Bickel et al.
BioMed Central
Page 1 of 2
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) 
with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine 
(245/300 mg) in naïve patients
M Bickel*1, A Bodtlaender2, G Knecht2, M Kurowski3, S Klauke2 and T Lutz2
Address: 1HIV Research and Treatment Unit, Frankfurt, Germany, 2Infektiologikum, Frankfurt, Germany and 3Therapia GmbH, Berlin, Germany
* Corresponding author    
Background
In the past years, once-daily (QD) dosing of antiretroviral
combination therapy has become an increasingly availa-
ble treatment option for HIV-1+ patients.
Methods
Open label study in which HIV-1+ patients treated with
SAQ/RTV (1000/100 mg BID) and two NRTIs with HIV-
RNA-PCR < 50 copies/ml were switched to SAQ/
RTV(2000/100 mg QD) with unchanged NRTI-backbone.
CD4-cells, HIV-RNA-PCR, SAQ and RTV drug-levels and
metabolic parameters were compared.
Summary of results
17 patients (15 male, 42 years), median CD4 456 ± 139/
μl were included so far. The median follow-up time is 4
months. The HIV-RNA-PCR remained <50 copies/ml for
all patients. Fasting metabolic parameters remained
unchanged. The SAQ AUC 0–12 h were significantly
higher when given QD vs. BID (median 29,400 vs. 18,500
ng*h/ml; p = 0.009), whereas the Cmin, Cmax and AUC
was lower for RTV when given QD vs. BID (7,400 vs.
11,700 ng*h/ml; p = 0.02).
Conclusion
In this ongoing study SAQ/RTV (2000/100 mg QD) was
well tolerated and demonstrated higher SAQ and lower
RTV drug levels as compared to the BID dosing schedule.
(Table 1 and Figure 1.)
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Table 1: 
baseline month 3 p-value
Glucose [mg/dl] 91 ± 12 91 ± 10 0.9
Triglycerides [mg/dl] 178 ± 106 161 ± 96 0.7
Total chol. [mg/dl] 199 ± 43 206 ± 46 0.8
HDL chol. [mg/dl] 43 ± 9 44 ± 8 0.8
LDL chol. [mg/dl] 131 ± 31 133 ± 33 0.6
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SAQ drug level BID vs. QDFigure 1
SAQ drug level BID vs. QD.
